Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 May 2017 17:33

RNS Number : 5192E
Verona Pharma PLC
08 May 2017
 

 

 

 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: 

Verona Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: 

Growth Equity Opportunities IV, LLC

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

May 2, 2017

6. Date on which issuer notified:

May 5, 2017

7. Threshold(s) that is/are crossed orreached: 

8% to 9% change at direct interest level

     
 

 

8. Notified details:

A: Voting rights attached to shares 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights 

Direct

Direct 

Indirect 

Direct

Indirect

Ordinary Shares

 

GB00B06GSH43

4,424,065

4,424,065

4,424,065

4,424,065

 

4.47%

 

 

US9250501064

 

 

5,333,328

5,333,328

 

5.39%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate 

Exercise/Conversion Period 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instrument

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date 

Exercise/Conversion period 

Number of voting rights instrument refers to

 

% of voting rights 

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

9,757,393

9.86%

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: 

 

Growth Equity Opportunities IV, LLC is a limited liability company formed in the State of Delaware, United States

New Enterprise Associates 15, L.P., a limited partnership formed in the State of Delaware, is its sole member

NEA Partners 15, L.P., a limited partnership formed in the State of Delaware, is its general partner

NEA 15 GP, LLC, a limited liability company formed in the State of Delaware, is its general partner

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

Figures are based on a total number of 99,014,164 Ordinary Shares outstanding, as per the Company's Announcement of May 2, 2017.

14. Contact name:

Louis Citron, New Enterprise Associates

15. Contact telephone number:

+1 (410) 842-4000

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUBPAUPMGQR
Date   Source Headline
30th Oct 20186:00 amGNWVerona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update
26th Oct 201810:12 amGNWData from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference
27th Sep 20187:00 amGNWVerona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018
13th Sep 20181:00 pmGNWVerona Pharma to Host Conference Call to Review Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International Congress
7th Aug 20187:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018
2nd Mar 20184:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20184:35 pmRNSPrice Monitoring Extension
30th May 20177:00 amRNSHolding(s) in Company
30th May 20177:00 amRNSHolding(s) in Company
25th May 20175:27 pmRNSHolding(s) in Company
23rd May 20178:44 amRNSHolding(s) in Company
16th May 20177:44 amRNSPartial Exercise of Over-Allotment Option
9th May 20173:36 pmRNSHolding(s) in Company
8th May 20175:33 pmRNSHolding(s) in Company
5th May 20173:32 pmRNSHolding(s) in Company
5th May 201712:15 pmRNSHolding(s) in Company
5th May 201711:36 amRNSHolding(s) in Company
3rd May 20176:02 pmRNSHolding(s) in Company
3rd May 20172:49 pmRNSBlock Listing Application and Review
3rd May 201712:34 pmRNSGrant of Options and RSUs and PDMR Dealings
2nd May 20176:10 pmRNSClosing of Global Offering and Total Voting Rights
2nd May 20177:00 amRNSDirector/PDMR Shareholding
28th Apr 20175:40 pmRNSDirector/PDMR Shareholding
27th Apr 20177:00 amRNSPricing of Offering and Approval to List on NASDAQ
19th Apr 20177:00 amRNSGlobal Offering and Application to List on NASDAQ
18th Apr 20177:00 amRNSFDA Authorisation to Proceed RPL554 Investigation
12th Apr 20171:19 pmRNSResult of AGM
4th Apr 20177:14 amRNSFiles Statement for Proposed Global Offering
4th Apr 20177:00 amRNSFiles Statement for Proposed Global Offering
4th Apr 20177:00 amRNS1st Patient Dosed in Ph2a Trial for RPL554 in CF
3rd Apr 20177:00 amRNSBoard Change
31st Mar 20177:00 amRNSCOPD Collaboration and New Commercial Director
22nd Mar 20177:00 amRNSServices Agreement with QuintilesIMS
20th Mar 20171:55 pmRNSPosting of Annual report & Notice of AGM
2nd Mar 20179:36 amRNSPDMR Dealing
27th Feb 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSNotice of Results
22nd Feb 20177:00 amRNSFirst COPD patient dosed with RPL554
13th Feb 20177:00 amRNSTotal Voting Rights & Block Listing Interim Review
8th Feb 20171:31 pmRNSResult of General Meeting and Share Consolidation
18th Jan 20177:00 amRNSPublication of Circular
11th Jan 20177:00 amRNSHolding(s) in Company
4th Jan 201710:16 amRNSHolding(s) in Company
29th Dec 20164:40 pmPRNIssue of Equity
23rd Nov 20169:17 amPRNRegistered Initial Public Offering in the US
28th Oct 20167:00 amRNSExercise of options
26th Oct 20167:00 amPRNSecond Venture and Innovation Award from the CF Trust
19th Oct 20161:00 pmPRNNotice of Cancellation of Trading on Xetra
28th Sep 201610:49 amRNSExercise of options
26th Sep 20167:00 amPRNAppointment of CFO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.